Scott Haden Kollins
Adjunct Professor in the Department of Psychiatry and Behavioral Sciences
Overview
Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals. Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA. He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
Selected Grants
A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD awarded by Purdue Pharma L.P. (Principal Investigator). 2014 to 2015
A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder (CEES ADHD) awarded by Ironshore Pharmaceuticals & Development, Inc (Principal Investigator). 2014 to 2015
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD) awarded by Alcobra Ltd. (Principal Investigator). 2014 to 2015
Amphetamine Extended-Release Oral Suspension in the Treatment of Children with ADHD: A Laboratory School Study awarded by Tris Pharma, Inc. (Principal Investigator). 2014 to 2015
Project 1: Evaluating New Nicotine Standards in Cigarettes - Supplement awarded by University of Pittsburgh (Co Investigator). 2013 to 2014
Elucidating links between ADHD symptoms and tobacco/alcohol use trajectories awarded by National Institutes of Health (Advisor). 2010 to 2014
Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence awarded by National Institutes of Health (Co Investigator). 2009 to 2014
A randomized, multicenter, double-blind, placebo-controlled, parallel group study of NT0102 Methylphenidate Polistirex Extended-Release Oral Disintegrating Tablets in children w/ADHD awarded by Neos Therapeutics, Inc (Principal Investigator). 2013 to 2014
Sensitivity to smoking reinforcement in women: menstrual cycle effects awarded by National Institutes of Health (Collaborator). 2011 to 2013
Ecological Momentary Assessment of Ad Lib Smoking in ADHD Smokers awarded by National Institutes of Health (Collaborator). 2011 to 2012
Pages
Kollins, Scott H. “Editorial: From risk prediction to action: leveraging electronic health records to improve pediatric population mental health.” J Child Psychol Psychiatry, vol. 61, no. 2, Feb. 2020, pp. 113–15. Pubmed, doi:10.1111/jcpp.13199. Full Text
Schechter, Julia, et al. “Effect of Prenatal Smoke Exposure on Birth Weight: The Moderating Role of Maternal Depressive Symptoms.” Nicotine Tob Res, vol. 22, no. 1, Jan. 2020, pp. 40–47. Pubmed, doi:10.1093/ntr/nty267. Full Text Open Access Copy
Lunsford-Avery, Jessica R., et al. “Sleep/Wake Regularity Associated with Default Mode Network Structure among Healthy Adolescents and Young Adults.” Sci Rep, vol. 10, no. 1, Jan. 2020, p. 509. Pubmed, doi:10.1038/s41598-019-57024-3. Full Text
Schrott, Rose, et al. “Cannabis use is associated with potentially heritable widespread changes in autism candidate gene DLGAP2 DNA methylation in sperm.” Epigenetics, vol. 15, no. 1–2, Jan. 2020, pp. 161–73. Pubmed, doi:10.1080/15592294.2019.1656158. Full Text
Mitchell, John T., et al. “Smoking abstinence effects on emotion dysregulation in adult cigarette smokers with and without attention-deficit/hyperactivity disorder.” Drug Alcohol Depend, vol. 205, Dec. 2019, p. 107594. Pubmed, doi:10.1016/j.drugalcdep.2019.107594. Full Text
Xue, Hong, et al. “Snacking frequency and dietary intake in toddlers and preschool children.” Appetite, vol. 142, Nov. 2019, p. 104369. Pubmed, doi:10.1016/j.appet.2019.104369. Full Text
“Corrigendum: Cigarette Smoking Progression Among Young Adults Diagnosed With ADHD in Childhood: A 16-year Longitudinal Study of Children With and Without ADHD.” Nicotine Tob Res, vol. 21, no. 10, Sept. 2019, p. 1449. Pubmed, doi:10.1093/ntr/nty260. Full Text
Engelhard, Matthew M., and Scott H. Kollins. “The Many Channels of Screen Media Technology in ADHD: a Paradigm for Quantifying Distinct Risks and Potential Benefits.” Curr Psychiatry Rep, vol. 21, no. 9, Aug. 2019, p. 90. Pubmed, doi:10.1007/s11920-019-1077-1. Full Text
Addicott, Merideth A., et al. “Methylphenidate increases willingness to perform effort in adults with ADHD.” Pharmacol Biochem Behav, vol. 183, Aug. 2019, pp. 14–21. Pubmed, doi:10.1016/j.pbb.2019.06.008. Full Text
Raman, Sudha, et al. “Driving the Point Home: Novel Approaches to Mitigate Crash Risk for Patients With ADHD.” Pediatrics, May 2019. Pubmed, doi:10.1542/peds.2019-0820. Full Text